Every round on record, with the sources behind each and the investors on them.
Groundbreaking immunotherapy treatments for solid tumors targeting cancer patients.
dispatchbio.comLinkedInBiotech
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The release reports $216 million raised since founding, not the Series A amount or a Series A running total. It states that Dispatch has operations in Philadelphia and San Francisco but does not identify headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $216M financing total | 2025-07-23 | Arch Venture Partners, Parker Institute for Cancer Immunotherapy | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The release reports $216 million raised since founding, not the Series A amount or a Series A running total. It states that Dispatch has operations in Philadelphia and San Francisco but does not identify headquarters. | ||||